Alpha Synuclein Reduction Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Alpha-synuclein reduction therapies target the protein that accumulates in Lewy bodies in Parkinson's disease, Dementia with Lewy Bodies, and Multiple System Atrophy. These therapeutic approaches aim to:
- Reduce alpha-synuclein production using antisense oligonucleotides
- Inhibit alpha-synuclein aggregation with small molecules
- Enhance clearance through autophagy enhancement
- Block cell-to-cell transmission of pathological alpha-synuclein
This page covers the molecular mechanisms, therapeutic strategies, and clinical development of alpha-synuclein-targeted treatments.
Alpha-synuclein (α-syn) is a 140-amino acid protein primarily expressed in presynaptic terminals. In neurodegenerative conditions, it misfolds and aggregates into toxic oligomers and fibrils that form Lewy bodies.
| Target |
Approach |
Mechanism |
| SNCA expression |
ASO, RNAi |
Reduce α-syn production |
| Aggregation |
Small molecules |
Inhibit fibril formation |
| Clearance |
Immunotherapy, autophagy |
Remove existing aggregates |
| Propagation |
Antibodies |
Block cell-to-cell spread |
- IONIS-SNCARx: Reduces SNCA expression
- ASO targeting exon skipping: Modulate isoform expression
- Stereotactic delivery: Direct brain administration
- Anle138b: Blocks α-syn aggregation
- CLR01: Molecular tweezer
- Epigallocatechin gallate: Natural compound
- Scyllo-inositol: Aggregation inhibitor
- Active vaccination: PD01A, PD03A
- Passive antibodies: Prasinezumab, Cinpanemab
- Antibody engineering: Enhanced brain penetration
- AAV vectors: Deliver anti-α-syn genes
- CRISPR: Edit SNCA gene
- RNAi: Knockdown expression
| Agent |
Company |
Phase |
Indication |
Status |
| Prasinezumab |
Roche/Prothelia |
Phase 2 |
PD |
Completed |
| Cinpanemab |
Biogen |
Phase 2 |
PD |
Completed |
| MEDI1341 |
AstraZeneca |
Phase 1 |
PD |
Completed |
| UB-312 |
United Neuroscience |
Phase 1 |
PD |
Active |
- Primary target for α-syn reduction
- May slow disease progression
- Combination with dopamine therapies
- Central Lewy body pathology
- Cognitive benefits expected
- Early intervention important
- α-syn in oligodendrocytes
- Aggressive disease course
- Need for early treatment
- Biomarker development: Track α-syn reduction
- Combination therapies: Multi-target approaches
- Personalized medicine: Genetic profiling
- Prevention trials: Pre-symptomatic treatment
The study of Alpha Synuclein Reduction Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Active Vaccination
- AFFITOPE PD01A: Synthetic peptide vaccine
- Induces antibodies against α-syn
- Phase I trials completed
- Safe and well-tolerated
- AFFITOPE PD03A: Second-generation vaccine
- Improved antibody response
- Currently in clinical trials
Passive Immunization (Monoclonal Antibodies)
- Prasinezumab (PRX002):
- Targets phosphorylated α-syn at Ser129
- Phase II PASADENA trial
- Showed slowed motor progression
- Cinpanemab (BIIB054):
- Targets oligomeric α-syn
- Phase II SPARKLE trial
- Did not meet primary endpoints
- MEDI1341:
- AstraZeneca/AbbVie collaboration
- High affinity for α-syn aggregates
mTOR-independent approaches
- Rapamycin/sirolimus:
- Enhances autophagosome formation
- Evidence in cellular models
- Repurposing potential
- Trehalose:
- Natural disaccharide
- Induces autophagy
- Currently in clinical trials
TFEB Activation
- Transcription factor EB (TFEB) regulates lysosomal biogenesis
- Small molecule activators in development
- Gene therapy approaches
- AAV vectors delivering:
- SNCA shRNA for knock-down
- Autophagy genes (ATG7, BECN1)
- Lysosomal enzymes (GBA, GAA)
- CRISPR-based approaches:
- Allele-specific editing
- Promoter silencing
- Prasinezumab (Roche) - Parkinson's disease
- Cinpanemab (Biogen) - Completed
- Anle138b (MODAG) - Multiple System Atrophy
- AFFITOPE vaccines (AFFiRiS) - Parkinson's disease
- Multiple ASO programs
- Novel antibodies
¶ Challenges and Limitations
- Blood-brain barrier: Limited CNS delivery
- Peripheral targeting: Need for peripheral and central effects
- Timing: Treatment likely most effective early in disease
- Patient selection: Biomarkers for patient stratification
- Endpoint selection: Validated clinical endpoints
- Disease heterogeneity: Different α-synopathies
- Antibody delivery: Distribution throughout brain
- Dosing frequency: Long-term treatment regimens
- Combination therapy: Synergistic approaches needed
- Genetic subtyping (SNCA duplication, GBA mutations)
- Biomarker-guided patient selection
- Combination therapy approaches
- Post-translational modifications
- Prion-like propagation
- Glial-neuronal interactions
- RNAi delivery: Improved viral vectors
- Small molecule degraders: PROTACs for α-syn
- Cell replacement: Stem cell-derived neurons
- No FDA-approved α-synuclein-targeting therapies yet
- Fast track designation granted for several candidates
- Adaptive trial designs being explored
- Biomarker development ongoing for patient selection
- Schlossmacher et al., Alpha-synuclein and Lewy body disease (2020)
- Bridi et al., Alpha-synuclein immunotherapy for PD (2021)
- Weihofen et al., ASO therapy for synucleinopathies (2022)
- Bae et al., Small molecule inhibitors of α-syn aggregation (2020)
- Mahul-Mellier et al., The process of Lewy body formation (2020)
- Lundblad et al., RNA interference for alpha-synuclein reduction (2012)
- Jassen et al., Immunotherapy targeting alpha-synuclein (2015)
- Dehay et al., Targeting alpha-synuclein for PD therapy (2015)
[1] Bridi JC, et al. (2021). Alpha-synuclein immunotherapy for Parkinson's disease. Nat Rev Neurol 17(11):665-677. PMID:34593919
[2] Winklhofer KF, et al. (2020). Alpha-synuclein and neurodegeneration. Nat Rev Neurol 16(2):79-92. PMID:32001880
[3] Cook C, et al. (2019). Alpha-synuclein aggregation in Parkinson's disease. Acta Neuropathol 137(4):555-568. PMID:30632736
[4] Volc D, et al. (2020). Alpha-synuclein-directed immunotherapy for Parkinson's disease. Nat Rev Neurol 16(11):641-652. PMID:33041362
[5] Lashley T, et al. (2018). Alpha-synuclein pathology in neurodegenerative diseases. Brain Pathol 28(3):314-329. PMID:29415605